MIPH Stock Overview
Produces medicines, medical and dental supplies, and dietary supplements in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MINAPHARM Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م167.28 |
| 52 Week High | ج.م294.70 |
| 52 Week Low | ج.م145.01 |
| Beta | -0.031 |
| 11 Month Change | 6.60% |
| 3 Month Change | -4.14% |
| 1 Year Change | -32.92% |
| 33 Year Change | 60.02% |
| 5 Year Change | 96.92% |
| Change since IPO | 1,740.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| MIPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | -1.6% |
| 1Y | -32.9% | 25.3% | 26.5% |
Return vs Industry: MIPH underperformed the EG Pharmaceuticals industry which returned 28.5% over the past year.
Return vs Market: MIPH underperformed the EG Market which returned 27.8% over the past year.
Price Volatility
| MIPH volatility | |
|---|---|
| MIPH Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in EG Market | 9.8% |
| 10% least volatile stocks in EG Market | 3.8% |
Stable Share Price: MIPH has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: MIPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | n/a | Wafik El Bardissi | www.minapharm.com |
MINAPHARM Pharmaceuticals produces medicines, medical and dental supplies, and dietary supplements in Egypt and internationally. The company produces veterinary and herbal medicines. It offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinary tract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, glaucoma, ocular infection and inflammation, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy.
MINAPHARM Pharmaceuticals Fundamentals Summary
| MIPH fundamental statistics | |
|---|---|
| Market cap | ج.م1.85b |
| Earnings (TTM) | -ج.م273.19m |
| Revenue (TTM) | ج.م3.92b |
0.5x
P/S Ratio-6.8x
P/E RatioIs MIPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIPH income statement (TTM) | |
|---|---|
| Revenue | ج.م3.92b |
| Cost of Revenue | ج.م2.91b |
| Gross Profit | ج.م1.01b |
| Other Expenses | ج.م1.28b |
| Earnings | -ج.م273.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.69 |
| Gross Margin | 25.70% |
| Net Profit Margin | -6.98% |
| Debt/Equity Ratio | 129.9% |
How did MIPH perform over the long term?
See historical performance and comparison